Table 2.
PCSM10 risk associated with GC (per 0.1 unit or dichotomized at ≥ 0.6 vs ≤ 0.6) in logistic regression models: univariate GC and GC adjusted for base clinical model or CAPRA-S (all patients [n = 561, 112 with PCSM10])
| Model | OR (95% CI) | p value | AUC of model (95% CI) | Increase in AUC from adding GC |
|---|---|---|---|---|
| GC (per 0.1 unit) | 1.48 (1.33, 1.64) | <0.001 | 0.73 (0.67, 0.78) | (NA) |
| CAPRA-S (per 1 unit) | 1.38 (1.27, 1.51) | <0.001 | 0.73 (0.68, 0.78) | (NA) |
| Base model | (NA)* | <0.001 | 0.77 (0.73, 0.83) | (NA) |
| GC (per 0.1 unit), adjusted for base model | 1.32 (1.19, 1.48) | <0.001 | 0.79 (0.75, 0.84) | (0.03) |
| GC (per 0.1 unit), adjusted for CAPRA-S | 1.34 (1.20, 1.50) | <0.001 | 0.76 (0.71, 0.82) | (0.03) |
| GC (> 0.6 vs ≤ 0.6) | 5.87 (3.76, 9.17) | <0.001 | 0.69 (0.64, 0.74) | (NA) |
| GC (> 0.6 vs ≤ 0.6), adjusted forbase model | 3.87 (2.36, 6.35) | <0.001 | 0.80 (0.76, 0.85) | (0.04) |
| GC (> 0.6 vs ≤ 0.6), adjusted for CAPRA-S | 3.91 (2.43, 6.29) | <0.001 | 0.77 (0.77, 0.81) | (0.04) |
AUC = area under the curve; CAPRA-S = Cancer of the Prostate Risk Assessment Postsurgical; CI = confidence interval; GC = Decipher genomic classifier; NA = not applicable; OR = odds ratio; PCSM = prostate cancer-specific mortality.
The base model includes preoperative prostate-specific antigen (continuous), prostatectomy Gleason score (7, 8, 9–10), prostatectomy stage (organ confined, extraprostatic extension, seminal vesicle involvement, lymph node metastasis). Because these are well established prognostic factors but are not the focus of this study, the individual odds ratios and 95% confidence intervals for these variables are not shown.